Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Compounding Definition Brings States Into Oversight Fold

This article was originally published in The Pink Sheet Daily

Executive Summary

State regulators seem to agree with FDA about confusion over regulatory responsibility, saying writing consistent definitions for compounding and manufacturing will help determine future FDA involvement.

You may also be interested in...

FDA Compounder Inspections: States Taking Early Leave

State inspectors did not accompany FDA for the full duration of facility inspections and now the agency is turning over the findings to them.

Compounding: FDA Refining Post-Inspection Hand-off To States

When the agency finds a traditional compounder during an inspection, it asks state boards of pharmacy to ensure corrections are made.

Compounding Warning Letter Format Unchanged Since Legislation

FDA’s first two warning letters since draft compounding guidances may be another way to encourage outsourcer registration.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts